Real-world evidence on cenobamate monotherapy in epilepsy
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
When billed and allowed amounts aren’t enough: HealthVerity proprietary market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
Top ways to close the evidence gap before year end: taXonomy Pathways
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Fierce Pharma Week 2025: Building audiences with the same data that built the drug
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
HealthVerity Helps Day: Giving back nationwide
At HealthVerity, community is at the heart of who we are. Each year, our team members come together...
The rise of conversational AI in healthcare using EHR data
AI agents are quickly becoming part of the clinical conversation. Since the release of large...
Measuring virtual care impact with closed claims from HealthVerity Marketplace
Digital health innovators and pharma leaders are under increasing pressure to show that new models...
Measuring cost savings of virtual PT with HealthVerity Marketplace closed claims
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
How HealthVerity transforms messy real-world data into trusted insights
(Part 2) In Part 1 we explored how HealthVerity Marketplace delivers high-quality,...
GLP-1 trends 2025: real-world data, patient outcomes & future therapies
Few areas of medicine have captured public interest over the past two years quite like...
Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...